This post was originally published on this site Alkahest’s experimental blood-derived protein GRF6019 helps maintain cognition and function in mild to moderate Alzheimer’s disease patients, results of a six-month Phase 2 clinical trial show. “These top-line results indicate a potential benefit of this plasma protein fraction in slowing the progression of cognitive decline in patients with…
This post was originally published on this site Blood levels of certain molecules— metabolites and amino acids — may help to identify people with Alzheimer’s disease who are more likely to improve their cognitive skills in response to aerobic exercise, a study suggests. These results were shared in the poster “Plasma Metabolites to Predict Response to Exercise…
This post was originally published on this site AC Immune is launching a Phase 1b/2a clinical trial to evaluate an investigational anti-tau vaccine called ACI-35.030 as a potential disease-modifying treatment for Alzheimer’s disease and other disorders characterized by the accumulation of tau protein. The presence of abnormal aggregates of beta-amyloid and tau proteins in the brain…
This post was originally published on this site Have you heard the saying, “Talking to yourself is OK as long as you don’t expect a response”? Most of us do it, and I believe that self-talk is particularly prevalent among caregivers. I am an audible self-talker, whispering declarations and questions to no one in particular.…
This post was originally published on this site To foster the cognitive stimulation of its Alzheimer’s disease (AD) residents, an Arkansas senior living center collaborated with the University of Arkansas – Fort Smith (UAFS) to produce recreational 3D-printed items. A set of large-scale, lightweight, and colorful plastic nuts and bolts were made especially for those Methodist…
This post was originally published on this site AZTherapies has completed enrollment for its Phase 3 COGNITE trial, testing the safety and efficacy of its investigational ALZT-OP1 for the treatment of early Alzheimer’s disease (AD). A total of 620 participants were enrolled following the screening of 1,800 patients, the company said. “With the COGNITE trial…
This post was originally published on this site A mutation in a gene linked to familial Alzheimer’s disease promotes the disease by reducing the points of contact between nerve cells and impairing neuronal communication, a study has found. A chemical compound, called EVP4593, partially rescued the mutation’s negative effects, suggesting it may hold a…
This post was originally published on this site This week people around the world celebrated International Day of Friendship. In 2011, the United Nations General Assembly designated July 30 as a day to recognize the power of friendship to address disharmony in the world by “accumulating bonds of camaraderie and developing strong ties of trust.”…
This post was originally published on this site The University of California, Berkeley (UC Berkeley) will receive an expected $47 million in a federal grant that will add advanced brain imaging to a pivotal study to determine whether lifestyle modifications can protect memory in those at risk of developing dementia. With the five-year grant from…
This post was originally published on this site Biopharmaceutical company Longeveron will use a $3 million Alzheimer’s Association grant to advance innovative research that uses adult stem cells to target neuroinflammation in people with mild Alzheimer’s disease (AD). Funding is through the organization’s Part the Cloud global research grant program, designed to find promising targets for…
